Skip to content
Open access

First-Line Antiretroviral Regimens and Risk of Incident Hypertension in People With HIV: A 15-Year Cohort Study

Oct 2026 · Open Forum Infectious Diseases · Vol 13 · 0 citations · 27 references
Medicine

Abstract

Abstract Background People with HIV (PWH) face a growing burden of cardiovascular disease. Integrase strand transfer inhibitors (INSTIs) have been linked to weight gain and possibly hypertension, but head-to-head data among contemporary regimens are scarce, and few studies analyze older and modern regimens together. We evaluated the incidence of hypertension in antiretroviral therapy (ART)-naive PWH initiating Spanish guidelines-recommended first-line regimens since 2009. Methods This study evaluated a retrospective cohort of ART-naive adults initiating first-line regimens from 2009 to 2024, grouped into non-nucleoside reverse transcriptase inhibitor (NNRTI), INSTI, and boosted protease inhibitor (PI)-based classes. Incident hypertension was defined by a composite of clinical diagnosis, antihypertensive initiation, or 2 consecutive measurements ≥ 140/90 mmHg. Time to hypertension was analyzed using Kaplan–Meir methods and Cox regression, with a prespecified INSTI subanalysis. Results Among 1134 participants (median age 34.1 years; 89.8% male), 205 (18.1%) developed hypertension over a median of 135.9 weeks (incidence 4.9/100 person-years). Hypertension-free survival differed by class (log-rank P = .005); INSTI-based ART was independently associated with higher risk than NNRTIs (adjusted HR 1.61; 95% CI 1.20–2.17). Within the INSTI subgroup (n = 437; incidence 7/100 person-years), 5-year cumulative hypertension ranged from 9% (EVG/c/FTC/TAF) to 37% (dolutegravir-based); dolutegravir-based regimens carried a >2-fold adjusted hazard versus EVG/c/FTC/TAF. Higher body mass index was independently predictive but did not abolish this signal. Conclusions In ART-naive PWH, INSTI-based regimens were associated with a higher incidence of hypertension than NNRTI-based regimens, whereas the comparison with PI-based regimens was not statistically significant. Dolutegravir-containing regimens were independently associated with incident hypertension supporting systematic blood pressure surveillance and further comparative studies.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.